Browsing by Author "Snow, Winter"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Developing a Rodent Model of Adverse Menopausal Symptoms
    (Office of the Vice Chancellor for Research, 2011-04-08) Snow, Winter; Federi, Lauren; Fitz, Stephanie; Janasik, Stephen; Penno, Daniel; Samuels, Brian; Carpenter, Janet; Skaar, Todd C.; Shekhar, Anantha; Johnson, Philip L.
    Menopause is a condition where severe depletion of estrogen levels leads to a cluster of adverse symptoms such as anxiety, cutaneous vasodilation/sudomotor "hot flashes", sleep disturbances, and appetite change (Freeman et al., 2005; Seritan et al., 2010). Previously, estrogen replacement therapy was the first line treatment for menopausal symptoms. However, it is no longer acceptable due to increased risk of cancer (Rossouw et al., 2002). Therefore there is a need for creating non-hormonal therapies to reduce the incidence of adverse menopausal-related symptoms. This is hindered by the limited understanding of menopausal symptoms and a lack of animal models of "hot flashes" (Nelson et al., 2006). Currently, the most accepted model of hot flashes is addicting female rats to morphine then inducing morphine withdrawal using naloxone (a ?-opioid receptor competitive antagonist) to provoke increases in tail temp (an indicator of cutaneous vasodilation). Yet, there is no evidence that the opioid system is disrupted in women with menopause [e.g., naloxone does not provoke "hot flashes" clinically (DeFazio et al., 1984)]. Here we induced a menopausal state by surgically removing the ovaries (OVEX) to deplete estrogen which induces a cluster of adverse menopause-like symptoms that include: 1) increased anxiety; 2) weight gain; and 3) disrupted diurnal skin and core body tempature changes. Additionally, we have developed an alternative model of "hot flashes" where administering yohimbine (an alpha2-adrenergic autoreceptor antagonist that provokes "hot flashes in menopausal women) resulted in "hot flash"-related increases in skin temp in OVEX, but not sham-OVEX, female rats.
  • Thumbnail Image
    Item
    A NOVEL APPROACH TO MODELING MENOPAUSAL SYMPTOMS AND THE ROLE OF THE OREXIN SYSTEM
    (Office of the Vice Chancellor for Research, 2012-04-13) Federici, Lauren; Fitz, Stephanie D.; Snow, Winter; Skaar, Todd C.; Carpenter, Janet; Shekhar, Anantha; Johnson, Philip L.
    Menopausal symptoms become prevalent in conditions associated with depletion of estrogens [e.g., ovariectomy surgery or with breast cancer treatments that block estrogen activity (e.g., tamoxifen or aromatase inhibition therapy)]. The primary menopause associated symptom is cutaneous vasodilation “hot flashes”, but also includes sleep and mood disruption (Freeman et al., 2005; Seritan et al., 2010). Although the cause of menopausal symptoms is poorly understood, it is well-established that the hypothalamus: 1) plays a critical role in thermoregulation, sleep wake activity and emotional responses; and 2) has high and fairly exclusive expression of both estrogen α and β receptors (Laflamme et al., 1998). A recently discovered neuropeptide called Orexin (ORX) is exclusively synthesized in the perifornical hypothalamus (PeF). This neuropeptide plays a critical role in arousal, anxiety (Johnson et al., 2010), and body temperature regulation (Rusyniak et al., 2011), but is also severely elevated in the brain of postmenopausal women (El-Sedeek et al., 2010) and reduced in control subjects following estrogen replacement. Therefore, loss of normal inhibitory control by estrogens of the ORX system may lead to menopausal-related symptoms, and ORX antagonists could constitute a potential novel treatment strategy for adverse menopausal symptoms. In support of this hypothesis, ovariectomized (OVEX), female rats, compared to sham controls, had significantly greater anxiety at baseline which was blocked by administration of an ORX1 receptor (ORX1R) antagonist (SB334867, 25mg/kg ip) or estrogen replacement. Administration of a sub-threshold dose of FG-7142 (a partial inverse GABAA receptor agonist, 3mg/kg ip) caused higher (~6°C) and longer tail skin flushes in OVEX rats, which was attenuated with similar pretreatment with an ORX1R antagonist or with estrogen replacement. These results indicate a novel role for both the GABA and ORX systems in menopausal symptoms and further research aims to elucidate the mechanisms of dysfunction of these systems in the menopausal state.